|NASDAQ: ATXI||Healthcare / Biotechnology / USA|
|1.05||+0.0005||+0.05%||Vol 89.30K||1Y Perf -89.14%|
|Mar 24th, 2023 10:54 DELAYED|
|0.01 0.95%||- -|
|Target Price||9.00||Analyst Rating||— 0.00|
|Potential %||756.74||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||0.43||Earnings Rating||Neutral|
|Market Cap||5.81M||Earnings Date||24th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||24th Mar 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||132.57K|
|Avg. Monthly Volume||818.82K|
|Avg. Quarterly Volume||906.74K|
Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 1.05 per share at the end of the most recent trading day (a -0.94% change compared to the prior day closing price) with a volume of 118.46K shares and market capitalization of 5.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Alexandra MacLean.
The one-year performance of Avenue Therapeutics Inc. stock is -89.14%, while year-to-date (YTD) performance is -9.48%. ATXI stock has a five-year performance of -98.72%. Its 52-week range is between 0.983 and 16.65, which gives ATXI stock a 52-week price range ratio of 0.43%
Avenue Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 14.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -870.59%, a ROC of -847.42% and a ROE of 5 775.10%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Avenue Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is 24th Mar 2023.
The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is — (0), with a target price of $9, which is +756.74% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.56, ATR14 : 0.10, CCI20 : -83.66, Chaikin Money Flow : -0.05, MACD : -0.04, Money Flow Index : 77.18, ROC : -0.94, RSI : 40.32, STOCH (14,3) : 10.34, STOCH RSI : 0.03, UO : 45.11, Williams %R : -89.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.
CEO: Alexandra MacLean
Telephone: +1 781 652-4500
Address: 1140 Avenue of the Americas, New York 10036, NY, US
Number of employees: 4
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.